The estimated Net Worth of Influence Ltd Strong is at least $54 million dollars as of 8 November 2021. Influence Strong owns over 4,000,000 units of ViewRay stock worth over $277,706 and over the last 6 years Influence sold VRAY stock worth over $53,751,000.
Influence has made over 3 trades of the ViewRay stock since 2019, according to the Form 4 filled with the SEC. Most recently Influence sold 4,000,000 units of VRAY stock worth $28,080,000 on 8 November 2021.
The largest trade Influence's ever made was buying 5,750,798 units of ViewRay stock on 6 December 2019 worth over $17,999,998. On average, Influence trades about 3,512,700 units every 176 days since 2018. As of 8 November 2021 Influence still owns at least 11,108,222 units of ViewRay stock.
You can see the complete history of Influence Strong stock trades at the bottom of the page.
Over the last 9 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun et Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: